Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,367.02 +3,820.24 (+6.42%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Merck & Co., Inc. (MRCK34.SA)
São Paulo - São Paulo Delayed price. Currency in BRL
Add to watchlist
At close: 05:10PM BRT
| Previous close | 82.31 |
| Open | 80.98 |
| Bid | 80.78 x 0 |
| Ask | 81.04 x 0 |
| Day's range | 80.88 - 81.12 |
| 52-week range | 61.00 - 85.35 |
| Volume | |
| Avg. volume | 7,868 |
| Market cap | 1.689T |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 139.86 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.36 (1.67%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
- Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
- Business Wire
Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
© 2024 Yahoo. All rights reserved.